# US 2019/0169695 A1 · Methods and systems for detecting sequence variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169695 A1
- Document ID: US20190169695A1
- Status: Published application
- Kind: A1
- Application number: 16/106,996
- Filed: 2018-08-21
- Published: 2019-06-06
- Earliest claimed: 2013-10-18
- Assignees: Seven Bridges Genomics Inc.
- Applicants: Seven Bridges Genomics Inc.
- Inventors: Deniz Kural
- Web page: https://patentgrep.com/patent/US20190169695A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 30/10: Sequence alignment; Homology search
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/16: Primer sets for multiplex assays
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The invention includes methods and systems for identifying diseased-induced mutations by producing multi-dimensional reference sequence constructs that account for variations between individuals, different diseases, and different stages of those diseases. Once constructed, these reference sequence constructs can be used to align sequence reads corresponding to genetic samples from patients suspected of having a disease, or who have had the disease and are in suspected remission. The reference sequence constructs also provide insight to the genetic progression of the disease.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A system for identifying cancer-induced genetic mutations, comprising:
at least one computer hardware processor; and
at least one non-transitory computer-readable storage medium storing processor-executable instructions that, when executed by the at least one computer hardware processor, cause the at least one computer hardware processor to perform:
aligning a first plurality of sequence reads from a non-cancerous sample from a subject to a reference sequence;
representing, in the non-transitory computer-readable storage medium, one or more differences between the first plurality of sequence reads and the reference sequence as two or more alternative paths in a first graph data structure comprising nodes and edges, wherein each alternative path is placed at a position in the first graph data structure where there is a difference between at least one sequence read and the reference sequence;
aligning a second plurality of sequence reads from a cancerous sample from the subject to the first graph data structure, wherein the aligning considers two or more alternative paths by looking backwards to any prior paths on the first graph data structure to find a maximum score; and
identifying one or more differences between the second plurality of sequence reads and the graph data structure as new mutations correlated with the cancer.

### Claim 22 (depends on 21)

The system of claim 21, wherein the reference sequence comprises a graph data structure.

### Claim 23 (depends on 21)

The system of claim 21, wherein the first graph data structure is a directed acyclic graph (DAG).

### Claim 24 (depends on 21)

The system of claim 21, wherein each node in the first graph data structure stores one or more nucleotide symbols.

### Claim 25 (depends on 24)

The system of claim 24, wherein each alternative path is created by breaking the reference sequence into nodes before and after the identified difference, and creating a path between the nodes that represents the reference sequence and another path between the nodes representing the identified difference, thereby creating the first graph data structure against which nucleic acid reads can be aligned.

### Claim 26 (depends on 21)

The system of claim 21, wherein the instructions further comprise:
preparing a second graph data structure representing the differences between the first plurality of sequence reads, the second plurality of sequence reads, and the reference sequence;
aligning a third plurality of sequence reads from an advanced cancerous sample from the subject to the second graph data structure; and
identifying one or more differences between the third plurality of sequence reads and the second graph data structure as new mutations correlated with the advanced cancerous sample.

### Claim 27 (depends on 26)

The system of claim 26, wherein the second plurality of sequence reads represents a major genetic clone due to the cancer.

### Claim 28 (depends on 26)

The system of claim 26, wherein the third plurality of sequence reads represent a minor genetic clone due to the cancer.

### Claim 29 (depends on 21)

The system of claim 21, wherein the instructions further comprise representing the new mutations correlated with the cancer as alternative paths in the first graph data structure.

### Claim 30 (depends on 21)

The system of claim 21, wherein the instructions further comprise aligning one or more sequence reads from a third plurality of sequence reads corresponding to a sample later collected from the same subject to the graph data structure, and monitoring cancer progression or recurrence based on the alignment.

### Claim 31 (depends on 21)

The system of claim 21, wherein the instructions further comprise reporting the new mutations correlated with the cancer to a health care provider.

### Claim 32 (depends on 21)

The system of claim 21, wherein the instructions comprise diagnosing the subject as having an advanced stage of the cancer based on the identified one or more differences between the second plurality of sequence reads and the first graph data structure.

### Claim 33 (depends on 32)

The system of claim 32, wherein the advanced stage of cancer is metastatic cancer.

### Claim 34 (depends on 21)

The system of claim 21, wherein the reference sequence is the human genome.

### Claim 35

A method of identifying cancer-induced genetic mutations, comprising using a processor coupled to a non-transitory computer-readable storage medium to perform:
aligning a first plurality of sequence reads from a non-cancerous sample from a subject to a reference sequence;
representing, in the non-transitory computer-readable storage medium, one or more differences between the first plurality of sequence reads and the reference sequence as two or more alternative paths in a first graph data structure comprising nodes and edges, wherein each alternative path is placed at a position in the first graph data structure where there is a difference between at least one sequence read and the reference sequence;
aligning a second plurality of sequence reads from a cancerous sample from the subject to the first graph data structure, wherein the aligning considers two or more alternative paths by looking backwards to any prior paths on the first graph data structure to find a maximum score; and
identifying one or more differences between the second plurality of sequence reads and the graph data structure as new mutations correlated with the cancer.

### Claim 36 (depends on 35)

The method of claim 35, wherein each alternative path is created by breaking the reference sequence into nodes before and after the identified difference, and creating a path between the nodes that represents the reference sequence and another path between the nodes representing the identified difference, thereby creating the first graph data structure against which nucleic acid reads can be aligned.

### Claim 37 (depends on 35)

The method of claim 35, further comprising:
preparing a second graph data structure representing the differences between the first plurality of sequence reads, the second plurality of sequence reads, and the reference sequence;
aligning a third plurality of sequence reads from an advanced cancerous sample from the subject to the second graph data structure; and
identifying one or more differences between the third plurality of sequence reads and the second graph data structure as new mutations correlated with the advanced cancerous sample.

### Claim 38 (depends on 35)

The method of claim 35, further comprising:
aligning one or more sequence reads from a third plurality of sequence reads corresponding to a sample later collected from the same subject to the graph data structure; and
monitoring cancer progression or recurrence based on the alignment.

### Claim 39 (depends on 35)

The method of claim 35, further comprising diagnosing the subject as having an advanced stage of the cancer based on the identified one or more differences between the second plurality of sequence reads and the first graph data structure.

### Claim 40 (depends on 35)

The method of claim 35, wherein the reference sequence is the human genome.
